{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:21:54Z","timestamp":1787242914278,"version":"build-2736575974"},"reference-count":42,"publisher":"Scientific Scholar","issue":"04","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>Objectives\u2003Malignant melanoma demonstrates frequently occurring mutations of genes in the serine\/threonine kinase pathway, namely BRAF, NRAS, and neurofibromin 1. There is rare documentation of a detailed analysis of these mutations in cases of melanoma among Indian patients. We present molecular features in cases of malignant melanoma, diagnosed at a tertiary cancer referral center in India, over a period of 8 years (2011\u20132018).<\/jats:p>\n                  <jats:p>Materials and Methods\u2003This study was performed on formalin fixed paraffin embedded tissues of 88 histologically confirmed cases of malignant melanoma. BRAF gene alterations were studied by both Sanger sequencing and real-time polymerase chain reaction techniques (n\u2009=\u200974). Molecular testing for BRAF and NRAS gene alterations was accomplished in 74\/88 cases (80%). Molecular test results were correlated with clinicopathological features using IBM SPSS Statistical software 25.0.<\/jats:p>\n                  <jats:p>Results\u2003The age ranged from 13 to 79 years (median\u2009=\u200957), with a M:F ratio of 1.4:1. BRAF mutations were observed in 12\/74 (16.21%) patients, including V600E (n\u2009=\u20097), A594T (n\u2009=\u20091), T599 = (n\u2009=\u20092), V600K (n\u2009=\u20091), and Q612P (n\u2009=\u20091), while NRAS mutations were observed in 6\/38 (15.7%) patients. Among various subtypes, nodular melanoma was the most frequent subtype (33%) among cutaneous malignant melanomas. Among non-cutaneous melanomas, mucosal melanomas were observed in 37.5% of cases.<\/jats:p>\n                  <jats:p>Conclusion\u2003This constitutes one of the few reports on comprehensive analysis of molecular alterations underlying melanomas in Indian patients. A larger sample size, with more extensive molecular markers, would yield additional information on the disease manifestation.<\/jats:p>","DOI":"10.1055\/s-0043-1760759","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T19:04:35Z","timestamp":1677783875000},"page":"359-370","source":"Crossref","is-referenced-by-count":3,"title":["BRAF V600E Mutations and Beyond: A Molecular Perspective of Melanoma from a Tertiary Cancer Referral Center of India"],"prefix":"10.25259","volume":"12","author":[{"given":"Vaibhavi","family":"Vengurlekar","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Molecular Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omshree","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Molecular Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Gurav","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Molecular Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Bapat","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Molecular Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nupur","family":"Karnik","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Wagh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Epari","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Rekhi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Ramadwar","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"e9509","DOI":"10.1097\/MD.0000000000009509","article-title":"Aberrations and clinical significance of BRAF in malignant melanoma: a series of 60 cases in Chinese Uyghur","volume":"97","author":"X Kang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","article-title":"Intratumor and intertumor heterogeneity in melanoma","volume":"10","author":"T M Grzywa","year":"2017","journal-title":"Transl Oncol"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"L Cheng","year":"2018","journal-title":"Mod Pathol"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence","volume":"74","author":"M H Nissan","year":"2014","journal-title":"Cancer Res"},{"key":"ref5","first-page":"14","article-title":"Clinical and therapeutic implications of melanoma genomics","volume":"2","author":"M Shaughnessy","year":"2018","journal-title":"J Transl Genet Genom"},{"issue":"02","key":"ref6","first-page":"24","article-title":"Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research","volume":"3","author":"P Bhatia","year":"2015","journal-title":"Ann Transl Med"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12885-017-3529-5","article-title":"Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care","volume":"17","author":"M V Heppt","year":"2017","journal-title":"BMC Cancer"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/ol.2014.2122","article-title":"Molecular alterations in clinical stage III cutaneous melanoma: correlation with clinicopathological features and patient outcome","volume":"8","author":"P Rutkowski","year":"2014","journal-title":"Oncol Lett"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"E Edlundh-Rose","year":"2006","journal-title":"Melanoma Res"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","article-title":"Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort","volume":"48","author":"L Si","year":"2012","journal-title":"Eur J Cancer"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5826\/dpc.0901a13","article-title":"BRAF mutation status in primary, recurrent, and metastatic malignant melanoma and its relation to histopathological parameters","volume":"9","author":"A Spathis","year":"2019","journal-title":"Dermatol Pract Concept"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1371\/journal.pone.0000236","article-title":"B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis","volume":"2","author":"S Ugurel","year":"2007","journal-title":"PLoS One"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ajco.12670","article-title":"Sunrise in melanoma management: time to focus on melanoma burden in Asia","volume":"13","author":"J W Chang","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4103\/ijc.IJC_612_17","article-title":"Clinicopathological study of malignant melanoma in a regional cancer center","volume":"55","author":"S Panda","year":"2018","journal-title":"Indian J Cancer"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4103\/0019-509X.180822","article-title":"A clinicopathologic study of malignant melanoma based on cytomorphology","volume":"53","author":"K Radhika","year":"2016","journal-title":"Indian J Cancer"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4103\/0973-1482.57122","article-title":"Malignant melanoma: a retrospective series from a regional cancer center in India","volume":"5","author":"K Sharma","year":"2009","journal-title":"J Cancer Res Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cancergen.2019.01.003","article-title":"Molecular evaluation of BRAF V600 mutation and its association with clinicopathological characteristics: first findings from Indian malignant melanoma patients","volume":"231-232","author":"F Ahmad","year":"2019","journal-title":"Cancer Genet"},{"issue":"06","key":"ref20","first-page":"PC12","article-title":"Changing trends of skin cancer: a tertiary care hospital study in Malwa Region of Punjab","volume":"10","author":"S T Lal","year":"2016","journal-title":"J Clin Diagn Res"},{"issue":"09","key":"ref21","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/PAS.0000000000000229","article-title":"Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach","volume":"38","author":"J Lasota","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"J Ferlay","year":"2010","journal-title":"Int J Cancer"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1755-148X.2010.00778.x","article-title":"Genetic and morphologic features for melanoma classification","volume":"23","author":"S M Broekaert","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4161\/cc.4.10.2026","article-title":"Analysis of BRAF mutation in primary and metastatic melanoma","volume":"4","author":"M Libra","year":"2005","journal-title":"Cell Cycle"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/ijc.20690","article-title":"International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification","volume":"114","author":"A Stang","year":"2005","journal-title":"Int J Cancer"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000071787","article-title":"Changing trends in numbers of deaths from malignant melanoma in Japan, 1955-2000","volume":"207","author":"H Ohtsuka","year":"2003","journal-title":"Dermatology"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0377-1237(09)80036-1","article-title":"Melanoma: a frequently missed diagnosis","volume":"65","author":"R Lakhtakia","year":"2009","journal-title":"Med J Armed Forces India"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jfma.2015.02.001","article-title":"Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan","volume":"115","author":"Y S Sheen","year":"2016","journal-title":"J Formos Med Assoc"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/exd.13321","article-title":"Mutational profiling of acral melanomas in Korean populations","volume":"26","author":"J H Shim","year":"2017","journal-title":"Exp Dermatol"},{"issue":"S 11","key":"ref30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12919-019-0175-8","article-title":"Low BRAF V600 mutation prevalence in primary skin nodular melanoma in Indonesia: a real-time PCR detection among Javanese patients","volume":"13","author":"H T Rinonce","year":"2019","journal-title":"BMC Proc"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/cas.13241","article-title":"Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a phase II study","volume":"108","author":"N Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.prp.2015.03.005","article-title":"Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma","volume":"211","author":"M B Aksenenko","year":"2015","journal-title":"Pathol Res Pract"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/CMR.0000000000000628","article-title":"Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review","volume":"30","author":"L D Guti\u00e9rrez-Casta\u00f1eda","year":"2020","journal-title":"Melanoma Res"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","article-title":"Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma","volume":"24","author":"B Devitt","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"issue":"08","key":"ref35","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/jdv.12910","article-title":"Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma","volume":"29","author":"M Pracht","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"J H Lee","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.dsi.2014.09.001","article-title":"Photoprotection in ethnic skin","volume":"32","author":"M Al-Jamal","year":"2014","journal-title":"Dermatologica Sinica"},{"issue":"15","key":"ref39","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-05-2447","article-title":"Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies","volume":"12","author":"G Saldanha","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1346-8138.12822","article-title":"BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients","volume":"42","author":"S Oyama","year":"2015","journal-title":"J Dermatol"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/bjc.2014.287","article-title":"Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma","volume":"111","author":"M S Carlino","year":"2014","journal-title":"Br J Cancer"},{"issue":"18","key":"ref42","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1158\/1078-0432.CCR-16-0758","article-title":"BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAF V600E mutant melanoma","volume":"23","author":"A Kulkarni","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.celrep.2019.09.009","article-title":"Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses","volume":"29","author":"T Botton","year":"2019","journal-title":"Cell Rep"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/PAS.0b013e318271249e","article-title":"Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions","volume":"37","author":"K J Busam","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/ajco.12574","article-title":"A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan","volume":"12","author":"W K Huang","year":"2016","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1760759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:48Z","timestamp":1781176368000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/braf-v600e-mutations-and-beyond-a-molecular-perspective-of-melanoma-from-a-tertiary-cancer-referral-center-of-india\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":42,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2023,12,20]]},"published-print":{"date-parts":[[2023,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1760759","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]}}}